BioSpace News Archive

Business

Collegium Reports Third Quarter 2022 Financial Results

Collegium Pharmaceutical, Inc., a leading, diversified specialty pharmaceutical company, reported its financial results for the quarter ended September 30, 2022 and provided a corporate update.

November 3, 2022
·
18 min read
Business

Cytokinetics Reports Third Quarter 2022 Financial Results

Cytokinetics, Incorporated reported financial results for the third quarter of 2022.

November 3, 2022
·
16 min read
Business

Rigel Reports Third Quarter 2022 Financial Results and Provides Business Update

Rigel Pharmaceuticals, Inc. reported financial results for the third quarter ended September 30, 2022, including sales of TAVALISSE® tablets for the treatment of adults with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

November 3, 2022
·
18 min read
Business

Exact Sciences Announces Third Quarter 2022 Results

Exact Sciences Corp. announced that the company generated revenue of $523 million for the third quarter ended September 30, 2022, compared to $456 million for the same period of 2021.

November 3, 2022
·
19 min read
Business

Karyopharm Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported business highlights and financial results for the quarter ended September 30, 2022.

November 3, 2022
·
19 min read
Pharm Country

Regeneron Announces Investor Conference Presentations - November 03, 2022

Regeneron Pharmaceuticals, Inc. will webcast management participation as follows.

November 3, 2022
·
1 min read
MedinCell’s Partner Teva Today Announced Refiling for Approval of mdc-IRM and Confirmed Planned Launch in the U.S. in H1 2023

MedinCell’s (Paris:MEDCL) partner, Teva, today announced that it recently completed the re-submission to a New Drug Application to the U.S. FDA for mdc-IRM, a risperidone subcutaneous Long-Acting Injectable (LAI) for the maintenance treatment of schizophrenia using MedinCell’s proprietary technology.

November 3, 2022
·
2 min read
Genetown

Apellis Announces Plans to Submit 24-Month Phase 3 Data to the FDA for Pegcetacoplan NDA for Geographic Atrophy (GA)

Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today provided an update on its New Drug Application (NDA) for intravitreal pegcetacoplan for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

November 3, 2022
·
6 min read
Business

Profound Medical Announces Third Quarter 2022 Financial Results

Profound Medical Corp., a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, reported financial results for the third quarter ended September 30, 2022.

November 3, 2022
·
12 min read
Business

Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2022 Financial Results and Corporate Updates

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor infiltrating lymphocyte, TIL, and peripheral-blood lymphocyte, PBL), today reported third quarter and year-to-date 2022 financial results and corporate updates.

November 3, 2022
·
13 min read